iECURE is emerging from stealth with $50 million and a mission to go after the “holy grail” of gene editing with an in vivo approach that is mutation agnostic.
The biotech will use the funds for a slate of gene insertion programs for liver disorders out of the lab of gene therapy pioneer Jim Wilson, M.D., Ph.D. at the University of Pennsylvania.